Equities

Torii Pharmaceutical Co Ltd

Torii Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,250.00
  • Today's Change135.00 / 3.28%
  • Shares traded75.80k
  • 1 Year change+18.22%
  • Beta0.5627
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

  • Revenue in JPY (TTM)58.84bn
  • Net income in JPY5.28bn
  • Incorporated1921
  • Employees583.00
  • Location
    Torii Pharmaceutical Co LtdTorii Nihombashi Bldg.3-4-1, Nihombashi Hon-choCHUO-KU 103-8439JapanJPN
  • Phone+81 332316811
  • Fax+81 352037333
  • Websitehttps://www.torii.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ASKA Pharmaceutical Holdings Co Ltd63.57bn5.98bn65.22bn762.0010.120.94297.831.03210.94210.942,243.732,263.170.70561.643.8683,419,940.006.634.638.445.8749.3846.949.406.761.71--0.106414.863.946.1278.0334.04-37.8923.36
Katakura Industries Co., Ltd.39.01bn2.90bn71.66bn1.04k23.170.875112.391.8487.8287.821,179.692,325.400.27832.215.1037,506,730.002.192.352.823.3438.2537.757.878.322.71--0.107618.8116.62-2.048.0918.87-7.4610.76
JCR Pharmaceuticals Co Ltd35.26bn-437.00m85.72bn934.00--1.4627.422.43-3.49-3.49281.91451.840.3380.47912.1537,747,320.00-0.38648.66-0.568113.4671.4474.51-1.1418.240.9827-0.81840.332530.6024.8313.1146.008.1918.5421.67
Kyorin Pharmaceutical Co Ltd119.73bn4.82bn95.30bn2.04k17.590.651710.310.795983.8383.832,084.192,263.350.67451.213.1858,635,650.002.713.053.363.7942.8747.114.024.761.74--0.159367.745.531.0212.68-4.987.41-7.06
Nxera Pharma Co Ltd29.28bn-3.71bn107.61bn350.00--1.59427.043.68-41.70-41.70332.11753.720.1942.576.6183,642,860.00-2.46-0.6588-2.76-0.703675.2789.83-12.68-4.463.90-6.020.5060---18.00---1,982.98------
Zeria Pharmaceutical Co Ltd78.88bn9.03bn117.77bn1.78k10.821.197.021.49204.82204.821,789.401,858.720.54181.503.7144,387,400.006.203.899.826.2873.2271.9311.447.570.8393--0.350835.0910.744.1424.7817.4920.775.29
Torii Pharmaceutical Co Ltd58.84bn5.28bn122.40bn583.0022.640.994921.482.08187.71187.712,093.334,271.840.44112.742.30100,924,500.003.966.524.397.3544.4649.558.9717.985.19--0.0024.1711.74-2.674.4428.76-20.3820.11
Mochida Pharmaceutical Co Ltd104.51bn4.53bn125.15bn1.52k26.140.917116.841.20127.75127.752,945.163,641.810.66391.803.4268,662,940.002.884.373.415.3149.6152.474.346.713.50----45.16-0.3641-1.26-31.61-11.6310.91-1.21
Towa Pharmaceutical Co Ltd235.95bn16.92bn161.76bn4.59k9.140.94824.590.6856343.72343.724,793.823,311.490.55821.493.6051,428,070.004.004.214.915.6335.9039.237.177.231.62--0.566621.019.1316.74634.803.7228.2010.86
KAKEN PHARMACEUTICAL CO., LTD.87.25bn18.24bn177.74bn1.14k8.030.9498.512.04481.71481.712,303.804,076.800.48641.983.8876,867,840.0010.176.8311.667.8760.6654.7820.9114.484.47--0.024351.25-1.29-5.2147.52-14.700.36390.00
Kissei Pharmaceutical Co Ltd81.07bn10.73bn180.48bn1.78k15.140.736611.822.23241.71241.711,825.834,969.030.32941.602.9845,568,860.004.383.614.753.9049.8849.4713.3112.694.15--0.005734.8711.980.89196.0015.286.5810.40
Data as of Nov 08 2024. Currency figures normalised to Torii Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

11.13%Per cent of shares held by top holders
HolderShares% Held
Effissimo Capital Management Pte Ltd.as of 08 Mar 2024588.20k2.04%
Amundi Japan Ltd.as of 07 Nov 2024528.63k1.84%
Zennor Asset Management LLPas of 31 May 2024416.60k1.45%
The Vanguard Group, Inc.as of 02 Oct 2024416.59k1.45%
Nomura Asset Management Co., Ltd.as of 03 Oct 2024332.50k1.16%
Nikko Asset Management Co., Ltd.as of 04 Oct 2024214.80k0.75%
Dimensional Fund Advisors LPas of 30 Sep 2024212.19k0.74%
Norges Bank Investment Managementas of 30 Jun 2024207.90k0.72%
Daiwa Asset Management Co. Ltd.as of 30 Sep 2024151.90k0.53%
Polar Capital LLPas of 30 Sep 2024135.00k0.47%
More ▼
Data from 31 May 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.